

Erratum to: Increased bioavailability of phenylephrine by co-administration of acetaminophen: results of four open-label, crossover pharmacokinetic trials in healthy volunteers

Hartley C. Atkinson¹ · Ioana Stanescu¹ · Isam I. Salem² · Amanda L. Potts³ · Brian J. Anderson⁴

Published online: 14 April 2015
© Springer-Verlag Berlin Heidelberg 2015

Erratum to: Eur J Clin Pharmacol (2015) 71:151–158
DOI 10.1007/s00228-014-1788-5

The original publication of this article contains a mistake in Table 2. The correct table is shown below:

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00228-014-1788-5>.

✉ Brian J. Anderson
briana@adhb.govt.nz

¹ AFT Pharmaceuticals Ltd, P O Box 33-203, Takapuna, Auckland 0740, New Zealand

² International Pharmaceutical Research Centre, 1 Queen Rania, Street - Sport City Circle, Amman 11196, Jordan

³ Clinical Solutions NZ Ltd, P O Box 10574, Te Rapa, Hamilton 3241, New Zealand

⁴ Department of Anaesthesiology, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand

Table 2 Phenylephrine non-compartmental pharmacokinetic parameters (mean (SD)) and bioequivalence (point estimate (90 % CI)) analysis.

	Study 1			Study 2			Study 3			Study 4		
	Treatment A	Treatment B		Treatment D	Treatment E		Treatment F	Treatment G		Treatment H	Treatment I	Treatment J
C_{max} ($\mu\text{g}\cdot\text{mL}^{-1}$)	3220.06 (1537.41)	873.82 (266.45)		2545.85 (1264.30)	2077.27 (862.80)		1597.96 (784.80)	1131.90 (674.70)		1850.89 (685.93)	1119.08 (596.17)	3695.81 (2495.09)
Treatment A/B	332.26 (260.55-423.71)			-			-			-		
Treatment E/D	-			83.32 (70.89 – 97.93)			-			-		
Treatment F/G	-			-			148.56 (98.01-225.15)			-		
Treatment H/I	-			-			-			171.75 (149.99 – 196.67)		
Treatment I/J	-			-			-			31.98 (27.92 – 36.61)		
Treatment H/J	-			-			-			54.92 (47.96 – 62.89)		
AUC_{0-4} ($\mu\text{g}\cdot\text{mL}^{-1}\cdot\text{h}$)	2219.80 (675.45)	1019.70 (269.56)		2088.5 (578.2)	1673.5 (512.79)		1598.70 (844.90)	1705.20 (858.04)		1317.4 (411.19)	1284.6 (396.37)	2492.5 (804.66)
Treatment A/B	212.27 (185.65-242.71)			-			-			-		
Treatment E/D	-			79.64 (72.56 – 87.44)			-			-		
Treatment F/G	-			-			212.27 (185.65-242.71)			-		
Treatment H/I	-			-			-			102.42 (95.01-110.40)		
Treatment I/J	-			-			-			51.71 (47.96 – 55.73)		
Treatment H/J	-			-			-			52.96 (49.12 – 57.08)		
$AUC_{0-\infty}$ ($\mu\text{g}\cdot\text{mL}^{-1}\cdot\text{h}$)	2311.40 (682.00)	1104.60 (271.97)		2192.0 (585.96)	1779.8 (510.38)		1842.10 (967.59)	1915.50 (825.34)		1478.8 (457.07)	1488.5 (516.24)	2646.1 (847.68)
Treatment A/B	204.39 (179.28-233.01)			-			-			-		
Treatment E/D	-			81.00 (73.97 – 88.72)			-			-		
Treatment F/G	-			-			92.78 (74.04-116.25)			-		
Treatment H/I	-			-			-			99.87 (94.03 – 111.73)		
Treatment I/J	-			-			-			55.97 (51.13 – 60.73)		
Treatment H/J	-			-			-			55.90 (52.41 – 62.26)		
T_{max} (h)	0.67 (0.25)	0.76 (0.34)		0.56 (0.27)	0.56 (0.19)		0.83(0.30)	0.71 (0.37)		0.46 (0.15)	0.55 (0.34)	0.52 (0.25)
$T_{1/2}$ (h)	1.23 (0.76)	1.35 (0.81)		1.73 (0.95)	1.91 (1.35)		6.91 (2.83)	5.91 (2.87)		4.19 (1.38)	3.56 (0.82)	3.02 (0.92)

Treatment A - 1000 mg acetaminophen + 300 mg ibuprofen + 10 mg phenylephrine HCl; Treatment B - 10 mg phenylephrine; Treatment D - 1000 mg acetaminophen + 10 mg phenylephrine HCl; Treatment E - 500 mg acetaminophen and 10 mg phenylephrine; Treatment F - 1000 mg acetaminophen + 5 mg phenylephrine HCl; Treatment G - 10 mg phenylephrine HCl; Treatment H - 1000 mg acetaminophen + 5 mg phenylephrine HCl; Treatment I - 10 mg phenylephrine HCl; Treatment J - 1000 mg acetaminophen + 10 mg phenylephrine HCl